Press Releases
Valeritas in the News
02/25/2016
Valeritas Announces Leadership and Board of Directors Changes
02/16/2016
Valeritas’ V-Go® Disposable Insulin Delivery Device Demonstrated Greater Glycemic Control, Less Insulin Utilization and Cost Effectiveness when Compared to Subcutaneous Multiple Daily Insulin Injections
11/03/2015
Valeritas’ V-Go® Disposable Insulin Delivery Device Enables Long-Term Care (LTC) Residents Better Glycemic Control with Far Fewer Injections and Decreases Nursing Labor Costs in LTC Settings
10/22/2015
Valeritas’ V-Go® Device Shows to Help Improve Compliance and Efficacy for Patients with Diabetes on Insulin + GLP-1 Therapy as well as Those who Switched from Subcutaneous Insulin Injections to V-Go®
10/22/2015
T2DM Patients Shown to Reduce A1C and Require Less Insulin Using Valeritas’ V-Go®
10/22/2015
Valeritas’ V-Go® Disposable Insulin Delivery Device Demonstrates Efficacy and Safety in Patients with Diabetes
10/07/2015
Valeritas Wins a Cardinal Health Supply Chain Excellence Award for Second Consecutive Year
08/25/2015
Valeritas is proud to share with you today that ‘Clinical Insights Into a New, Disposable Insulin Delivery Device’ is published in the Summer 2015 edition of Diabetes Spectrum, the journal of the American Diabetes Association.
08/06/2015
A1C Levels and Insulin Requirements Are Shown to Decrease When Patients with Diabetes Switch to Valeritas’ V-Go® Device Coupled with Diabetes Education
06/08/2015
Real-World Study Data Demonstrating that Valeritas’ V-Go Consistently Reduces A1C Levels and Decreases Insulin Requirements for Patients with Diabetes Regardless of Baseline A1C Presented at ADA 2015
06/04/2015
Valeritas Places Top 3 Out of 240 Posters in AACE’s General Poster Competition
05/18/2015
Study Shows that Valeritas’ V-Go® Improves Blood Glucose Control and Reduces Insulin Requirements in Residents of Long Term Care Facilities
05/15/2015
Real-World Data from Three Separate Studies Demonstrate that Valeritas’ V-Go® Significantly Reduces A1c and Lowers Total Daily Insulin Dose for Patients with Diabetes
04/09/2015
Study Analysis Shows Valeritas' V-Go® Device Helps Reduce Diabetes Management Cost for Type 2 Diabetes Patients by Improving Glycemic Control and Reducing Insulin Doses
10/20/2014
Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award
05/15/2014
Interim Analysis Suggests that Delivery of Insulin via Valeritas' V-Go® Shows Promise in Improving Glycemic Control for Patients with Type 2 Diabetes Previously Taking Long-Acting Insulin
06/22/2013
Valeritas Announces New Findings from Observational Study Suggesting That Delivery of Insulin via V-Go® May Improve Glycemic Control and Reduce Total Daily Insulin Dose for Patients with Type 2 Diabetes
06/04/2013
Valeritas Closes $100 Million Financing
05/22/2013
Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
05/01/2013
New Interim Analysis From Observational Study Suggests That Delivery of Insulin via Valeritas' V-GO Shows Promise in Improving Glycemic Control For Patients With Type 2 Diabetes
12/11/2012
Valeritas Raises Record Funding for Central Massachusetts Chapter of American Diabetes Association
11/20/2012
Valeritas named Life Science Company of the year by the New Jersey Technology Council
11/12/2012
Valeritas announces the publication of a retrospective analysis of patient-reported data on the V-Go in the current issue of Endocrine Practice
09/12/2011
Valeritas Announces $150 Million Financing
07/25/2011
Valeritas Receives European CE Mark Approval for the V-Go® Disposable Insulin Delivery Device
03/01/2011
Valeritas Receives FDA 510(k) Clearance for the V-Go® Disposable Insulin Delivery Device for Use with NovoLog®
12/08/2010
Valeritas Receives FDA 510(k) Clearance for the V-Go® Disposable Insulin Delivery Device
03/17/2010
Valeritas Announces Appointment of New CFO - Former Amicus Therapeutics Chief Financial Officer James E. Dentzer Joins Executive Team
06/01/2009